A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prosta...

by Agarwal, N., Azad, A., Benzaghou, F., Carles, J., Chowdhury, S., Kerloeguen, Y., Kimura, A., Mcgregor, B., Merseburger, A.S, Mohamed, N., Oudard, S., Pal, S., Panneerselvam, A., Saad, F., Soares, A., Wang, F.
Published 2022